ReviewGenes & diseases2025
Role of chitinase-3-like protein 1 in liver diseases: A comprehensive review.
Review in Genes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression.Medicinal research reviews · 2026Review
- Association of Serum Chitinase-3-Like Protein 1 with Liver Fibrosis Severity in Autoimmune Liver Diseases.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitinase-3-like protein 1 (CHI3L1) is part of the glycoside hydrolase family 18. Despite lacking enzymatic activity, its unique structure allows it to bind to ligands, altering its steric configuration to mediate cell proliferation, inflammation, fibrosis, and carcinogenesis. In liver disease, CHI3L1 serves as a common diagnostic biomarker for hepatitis-related fibrosis. Additionally, CHI3L1 can predict the risk of non-alcoholic steatohepatitis, the progression of hepatic fibrosis, and the prognosis of alcoholic liver disease and hepatocellular carcinoma. It also aids in diagnosing and staging non-alcoholic fatty liver disease-related and alcoholic liver disease-related fibrosis, and in monitoring hepatitis-related fibrosis treatment. Furthermore, CHI3L1 is secreted by various cells, including hepatocytes, hepatic stellate cells, macrophages, and mesenchymal stem cells, to regulate hepatic injury, fibrosis, steatosis, and hepatocellular carcinoma through different signaling pathways. This review highlights CHI3L1's dual roles as both a biomarker and regulator in various liver diseases, aiming to broaden researchers' understanding of its potential applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.